Firm advances in sclerodermatous disorders - 14/12/22
Doi : 10.1016/j.jaad.2022.11.021
Warren R. Heymann, MD ⁎ 
Division of Dermatology, Cooper Medical School of Rowan University, Marlton, New Jersey
∗Correspondence to: Warren R. Heymann, MD, Division of Dermatology, Cooper Medical School of Rowan University, 100 Brick Road – Suite 306, Marlton, NJ 08053.Division of DermatologyCooper Medical School of Rowan University100 Brick Road – Suite 306MarltonNJ08053
Abbreviation used : 3DS
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2022
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 88 - N° 1
P. 27-28 - gennaio 2023 Ritorno al numero
Articolo precedente
- This Month in JAAD International: January 2023: Toward a more inclusive vision of cosmetic surgery
- Jonathan Kantor
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
- April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim A. Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, Elizabeth Colston, John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?